Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …

Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1)
exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion …

The incretin system is an essential metabolic axis that regulates postprandial metabolism.
The two incretin peptides that enable this effect are the glucose-dependent insulinotropic …

Diabetes Mellitus (DM) is a multi-factorial chronic health condition that affects a large part of
population and according to the World Health Organization (WHO) the number of adults …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

Despite the successful development of new therapies for the treatment of type 2 diabetes,
such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose …

Abstract Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option
for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the …

Background Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved for the
treatment of type 2 diabetes and obesity and elicit robust improvements in glycemic control …

Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to
determine whether the metabolic action of GIP adds to the established clinical benefits of …